{"id":"W1983697728","doi":"10.2165/11596340-000000000-00000","title":"Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients","year":2011,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Darunavir; Raltegravir; Ritonavir; Medicine; Maraviroc; Viral load; Regimen; Adverse effect; Internal medicine; Integrase inhibitor; Clinical endpoint; Gastroenterology; Virology; Pharmacology; Randomized controlled trial; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007170171,0.000204715,0.0003047742,0.000191188,0.00003930422,0.000006570263,0.00008204192,0.00008704461,0.0005471301],"category_scores_gemma":[0.00002813925,0.0001706533,0.00005972593,0.0002955191,0.00005849835,0.00009816742,0.00003074199,0.00009648638,0.0003898131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003846205,"about_ca_system_score_gemma":0.00009340543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004825919,"about_ca_topic_score_gemma":0.0003933756,"domain_scores_codex":[0.9988166,0.00003414377,0.0002787435,0.00032408,0.0002064484,0.0003399873],"domain_scores_gemma":[0.9995031,0.00003794356,0.00004915057,0.0002660031,0.00002903402,0.0001147164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001604628,0.002191548,0.8901406,0.00001205255,0.00007668872,0.0002001249,0.06632894,5.139723e-7,0.0000351503,0.00008339802,0.0003005394,0.03902584],"study_design_scores_gemma":[0.04620121,0.001167443,0.9321352,0.0002146418,0.00009190747,0.000003759215,0.006488275,0.00009906124,0.003867631,0.0001330713,0.009116902,0.0004809037],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9508016,0.00009568496,0.000001416363,0.0001357241,0.0002294894,0.000538482,0.000004283546,0.00004695158,0.04814638],"genre_scores_gemma":[0.9946605,0.00006523075,0.001105882,0.000049348,0.00001737751,0.0001090654,0.0001188051,0.00002144596,0.003852361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05984066,"threshold_uncertainty_score":0.6959038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04272275973899473,"score_gpt":0.290875164831624,"score_spread":0.2481524050926293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}